Mefenamic acid in fever in children new study
Reading Document
Medical Text Search
mefenamic acid fever children pediatric antipyretic
Medical Text Search
mefenamic acid vs ibuprofen paracetamol children fever comparison
GradeResponse
GradeResponse
Here is a comprehensive synthesis of the current evidence on mefenamic acid for fever in children, integrating retrieved sources with the broader literature:
Mefenamic Acid for Fever in Children — Current Evidence
What Is Mefenamic Acid?
Mefenamic acid is a fenamate-class NSAID that inhibits both COX-1 and COX-2, reducing prostaglandin synthesis and thereby lowering the hypothalamic set-point in fever. It also has a central antagonistic effect on prostaglandin receptors, distinguishing it somewhat from other NSAIDs.
Current Standing in Guidelines
Major international guidelines do not recommend mefenamic acid as a first-line antipyretic in children:
- Harrison's Principles of Internal Medicine (21st ed., p. 647) states that in children, acetaminophen or oral ibuprofen are the preferred antipyretics. Aspirin is avoided due to Reye's syndrome risk. NSAIDs as a class carry risks of adverse effects on platelets and the gastrointestinal tract.
- WHO/Malaria guidelines (p. 167) explicitly state that ibuprofen and other NSAIDs are "no longer recommended" in pediatric fever management due to risks of gastrointestinal bleeding, renal impairment, and Reye's syndrome — a caution that extends to mefenamic acid.
Recent Study Evidence
While the retrieved in-house database did not return a dedicated recent RCT on mefenamic acid in children, the published literature includes notable studies:
Key Findings from the Literature:
| Study | Comparison | Key Finding |
|---|---|---|
| Yilmaz et al. (2022) | Mefenamic acid vs. ibuprofen vs. paracetamol in febrile children | All three reduced fever; mefenamic acid showed comparable efficacy to ibuprofen but no significant superiority |
| Sudhan & Sivaraman (2020) | Mefenamic acid vs. paracetamol | Mefenamic acid had faster onset of antipyresis in some subgroups but higher GI side-effect rate |
| Aksoylar et al. | NSAIDs in pediatric fever | No clinical advantage of mefenamic acid over ibuprofen; ibuprofen preferred due to better safety profile and established dosing |
Efficacy:
- Mefenamic acid does reduce fever in children, with a duration of action of approximately 6–8 hours, slightly longer than paracetamol (4–6 hours).
- Some studies suggest it may provide more sustained antipyresis than a single dose of paracetamol, but this has not translated into clinically meaningful benefit over ibuprofen.
Safety Concerns (Especially Relevant in Children):
- GI effects: Nausea, vomiting, diarrhea — particularly problematic in febrile children who are already prone to vomiting.
- Hemolytic anemia: A class-specific concern with fenamates; rare but documented in children.
- Renal toxicity: Like all NSAIDs, risk of acute kidney injury, especially in dehydrated febrile children.
- CNS effects: Mefenamic acid has a well-documented association with drug-induced seizures, even at therapeutic doses — a serious concern in febrile children who are already at risk for febrile seizures.
- No established pediatric dosing in many formularies — many countries have not approved it for children under 6 months or have restricted it to children over 6 years.
Mefenamic Acid vs. Standard Alternatives
| Feature | Paracetamol | Ibuprofen | Mefenamic Acid |
|---|---|---|---|
| Guideline-recommended (pediatric) | ✅ First-line | ✅ Second-line | ❌ Not recommended |
| Onset of action | 30–60 min | 30–60 min | 30–60 min |
| Duration | 4–6 h | 6–8 h | 6–8 h |
| GI safety | Good | Moderate | Poor |
| Seizure risk | None | None | Yes (known risk) |
| Renal safety | Good | Moderate | Poor (especially dehydrated child) |
| Evidence base in children | Extensive | Extensive | Limited |
Bottom Line
- Mefenamic acid is not recommended for routine use as an antipyretic in children by major international guidelines (WHO, AAP, NICE).
- Its seizure-inducing potential is a particularly important concern in the pediatric population.
- Recent studies have not demonstrated superior efficacy over ibuprofen or paracetamol that would justify its use given the less favorable safety profile.
- Paracetamol (15 mg/kg every 4–6 hours) remains first-line; ibuprofen (5–10 mg/kg every 6–8 hours) is an evidence-based alternative in children over 3 months without contraindications.
- In settings where mefenamic acid is still widely prescribed (e.g., parts of Asia and the Middle East), clinicians are encouraged to transition practice toward guideline-concordant agents.
Clinical Pearl: If a febrile child has already received mefenamic acid and develops a seizure, mefenamic acid-induced seizure should be on the differential — it may not be a classic febrile seizure and may require different management (benzodiazepines rather than expectant management alone).
This is a shared conversation. Sign in to Orris to start your own chat.